Physician profile
Vanaja Sureddi
NPI 1184895286
$3,822.69
in general payments reported to CMS, 2019-2025
31 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $638 · 2021: $653 · 2022: $564 · 2023: $598 · 2024: $631 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.26 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $653.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $564.70 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $392.09 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $307.28 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $250.68 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $230.69 | 2022-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $198.44 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.77 | 2020-2025 | Xifaxan |
| Amgen INC. | $145.07 | 2023-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $137.77 | 2019-2021 | |
| Abbott Laboratories | $95.71 | 2021-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $79.35 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $65.08 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.88 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $57.84 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $52.58 | 2023 | Quviviq |
| Eisai INC. | $45.85 | 2020-2021 | |
| Gilead Sciences, INC. | $40.33 | 2021-2024 | |
| Allergan, INC. | $36.95 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.23 | 2024 | Eliquis |
| Intuitive Surgical, INC. | $26.74 | 2020 | |
| Medtronic, INC. | $24.36 | 2025 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $21.03 | 2023 | |
| Esperion Therapeutics, INC. | $19.51 | 2022 | |
| Smith+Nephew, INC. | $19.27 | 2024 | Collagenase Santyl |
| Alnylam Pharmaceuticals INC. | $19.10 | 2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $17.87 | 2022 | |
| Abiomed | $17.28 | 2024 | Impella |
| Ibsa Pharma INC. | $16.99 | 2020 | |
| Merck Sharp & Dohme LLC | $16.47 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanaja Sureddi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.